BioScrip (BIOS) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BIOS Hot Sheet
Join SI Premium – FREE
BioScrip (NASDAQ: BIOS) reported Q4 EPS of ($0.13), $0.05 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $243.8 million versus the consensus estimate of $238.3 million.
Same store revenue growth (excluding closed locations) for the quarter grew $10.3 million or 4.4% year over year on the strength of same store patient census growth of 8.4% for the same year over year period.
GUIDANCE:
BioScrip sees FY2016 EPS of ($0.39)-($0.19), versus the consensus of ($0.12).
For earnings history and earnings-related data on BioScrip (BIOS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- SmartRent (SMRT) Reports In-Line Q3 EPS
- Flutter Entertainment plc (FLUT) Misses Q3 EPS by 525c; lowers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
